Stellar Pharmaceuticals Inc. Announces Record First Quarter Financial Results and Profitability

LONDON, ONTARIO--(Marketwire - June 04, 2009) - Stellar Pharmaceuticals Inc. (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost effective products for select health care markets, today announced that Stellar finished the period with the highest revenues it has ever reported for a first quarter. Stellar's total revenues for the first quarter increased by 46.5% to $772,500 compared to $527,400 for the same period in 2008. The growth in revenue was strong in all markets, with the more established Canadian market up over 28% and international sales of NeoVisc and Uracyst up 224.4%. International sales have been strengthened with new partners in key European markets for Uracyst. Reorders early in the 2nd quarter from these new licensees is encouraging and increases our expectations for the year.

The strong revenue growth led to Gross profit being up 43.6% for the quarter, which resulted in net income for the period of $25,200 compared to a loss of $98,800 for the same quarter in 2008.

"The results of this quarter and subsequent events leads us to believe that the corporate strategies we have in place are finally showing the results we anticipated." said Peter Riehl, Stellar's President and CEO, " We are very encouraged by these results and look forward to a very productive year ahead."

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

                       STELLAR PHARMACEUTICALS INC.

                         CONDENSED BALANCE SHEETS
                     (Expressed in Canadian Dollars)

                                 ASSETS

                                                   As at              As at
                                          March 31, 2009  December 31, 2008
                                          --------------- ------------------
CURRENT                                       (Unaudited)          (Audited)

 Cash and cash equivalents                   $ 2,340,735        $ 2,105,966
 Accounts receivable                             317,936            549,055
 Inventories                                     215,603            212,445
 Loan receivable                                  18,369             18,369
 Prepaid, deposits and sundry receivables        236,799            130,515
                                          --------------- ------------------
                                               3,736,851          3,380,901
PROPERTY, PLANT AND EQUIPMENT                  1,235,801          1,270,257
OTHER ASSETS                                      72,112             65,495
                                          --------------- ------------------
                                             $ 5,044,764        $ 4,716,653
                                          --------------- ------------------
                                          --------------- ------------------

                            LIABILITIES

CURRENT
 Accounts payable                            $   415,256        $   173,812
 Accrued liabilities                             270,032            186,201
 Deferred revenues                                   700              1,749
                                          --------------- ------------------
                                                 685,988            361,762
                                          --------------- ------------------

CONTINGENCIES AND COMMITMENTS

                   SHAREHOLDERS' EQUITY
CAPITAL STOCK
AUTHORIZED
 Unlimited  Non-voting, convertible,
             redeemable, and retractable
             preferred shares with no
             par value
 Unlimited  Common shares with no par
             value
ISSUED
 23,555,040  Common shares (2008 -
              23,702,540)                      8,209,778          8,261,403
    (60,000) Treasury shares (2008 -
              (147,500))                         (21,292)           (51,625)
             Additional paid-in capital
              for cancelled common shares          2,329              2,329
             Additional paid-in capital
              options - outstanding               35,965             35,965
                      - expired                  722,372            722,372
                                          --------------- ------------------
                                               8,949,152          8,970,444

DEFICIT                                       (4,590,376)        (4,615,553)
                                          --------------- ------------------
                                               4,358,776          4,354,891
                                          --------------- ------------------
                                             $ 5,044,764        $ 4,716,653
                                          --------------- ------------------
                                          --------------- ------------------



                       STELLAR PHARMACEUTICALS INC.

                CONDENSED INTERIM STATEMENTS OF OPERATIONS
                AND COMPREHENSIVE INCOME (LOSS) AND DEFICIT
                     (Expressed in Canadian Dollars)

                              (Unaudited)

                                                 For the Three Month Period
                                                       Ended March 31
                                                    2009               2008
                                            -------------      -------------
                                                                   (Note 17)

PRODUCT SALES                               $    544,419       $    329,456
COST OF PRODUCTS SOLD                            154,955             97,327
                                            -------------      -------------
MARGIN ON PRODUCTS SOLD                          389,464            232,129

ROYALTY AND LICENSING REVENUES                   228,096            197,956
                                            -------------      -------------

GROSS PROFIT                                     617,560            430,085
                                            -------------      -------------

EXPENSES
 Selling, general and administrative             578,052            490,991
 Research and development                          5,608             53,818
 Amortization (non-manufacturing property,
  plant and equipment)                            13,698             13,167
                                            -------------      -------------
                                                 597,358            557,976
                                            -------------      -------------

INCOME (LOSS) FROM OPERATIONS                     20,202           (127,891)
INTEREST AND OTHER INCOME                          4,975             29,074
                                            -------------      -------------
NET INCOME (LOSS) AND COMPREHENSIVE
 INCOME (LOSS) FOR THE PERIOD                     25,177            (98,817)

DEFICIT, beginning of period                  (4,615,553)        (4,576,621)
                                            -------------      -------------

DEFICIT, end of period                      $ (4,590,376)      $ (4,675,438)
                                            -------------      -------------
                                            -------------      -------------

EARNINGS (LOSS) PER SHARE                   $       0.00       $       0.00
                                            -------------      -------------
                                            -------------      -------------

WEIGHTED AVERAGE NUMBER OF
 COMMON SHARES OUTSTANDING                    23,527,318         23,822,540
                                            -------------      -------------
                                            -------------      -------------



                       STELLAR PHARMACEUTICALS INC.

                CONDENSED INTERIM STATEMENTS OF CASH FLOWS
                      (Expressed in Canadian Dollars)

                               (Unaudited)

                                                 For the Three Month Period
                                                       Ended March 31
                                                    2009               2008
                                            -------------      -------------

CASH FLOWS FROM OPERATING ACTIVITIES -
 Net income (loss)                          $     25,177       $    (98,817)
 Items not affecting cash
  Amortization                                    34,995             30,383
  Unrealized foreign exchange (gain) loss          1,394            (13,150)
  Issuance of equity instruments for
   services rendered                                   -              5,589
 Change in non-cash operating assets and
  liabilities                                    203,044           (112,184)
                                            -------------      -------------

CASH FLOWS PROVIDED BY (USED IN)
 OPERATING ACTIVITIES                            264,610           (188,179)

CASH FLOWS USED IN INVESTING ACTIVITIES -
 Additions to property, plant and equipment         (197)           (15,906)
 Increase in other assets                         (6,957)            (6,063)
                                            -------------      -------------

CASH FLOWS USED IN INVESTING ACTIVITIES           (7,154)           (21,969)
                                            -------------      -------------

CASH FLOWS USED IN FINANCING ACTIVITIES -
 Repurchase of common shares for cash            (21,292)                 -
                                            -------------      -------------

CASH FLOWS USED IN INVESTING ACTIVITIES          (21,292)                 -
                                            -------------      -------------

EFFECT OF EXCHANGE RATES ON CASH HELD IN 
 FOREIGN CURRENCY                                 (1,395)            13,150
                                            -------------      -------------
CHANGE IN CASH AND CASH EQUIVALENTS              234,769           (196,998)
CASH AND CASH EQUIVALENTS, beginning of
 period                                        2,105,966          3,211,126
                                            -------------      -------------
CASH AND CASH EQUIVALENTS, end of period    $  2,340,735       $  3,014,128
                                            -------------      -------------
                                            -------------      -------------


Contacts:
Stellar Pharmaceuticals Inc.
Peter Riehl
President & CEO
(800) 639-0643 or (519) 434-1540
Corpinfo@StellarPharma.com

Stellar Pharmaceuticals Inc.
Arnold Tenney
(416) 587-3200

MORE ON THIS TOPIC